Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel + goserelin before radical prostatectomy for very high-risk locally advanced prostate cancer
ChiCTR-IPC-14005453Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center Department of Urology
- Start
- Dec 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel and goserelin in prostate cancer (PCa) (2 arms), sponsored by Fudan University Shanghai Cancer Center Department of Urology. Primary endpoint: 2-year PSA biochemical recurrence rate. Planned start Dec 2014; status: not yet recruiting.
02
Drugs
docetaxelgoserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR-IPC-14005453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPC-14005453.